Advertisements

Methergine Tablets

Quick links to important sections

Methergine Tablets

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Methergine Tablets

Property Description
Active Ingredient Methylergonovine maleate
Form Tablet (Oral)
Pharmacological Class Ergot Alkaloid Derivative, Uterotonic Agent
Common Purpose Supports uterine tone and firmness
Origin Semi-synthetic

Methergine Tablets are a prescription-only medication primarily defined by its active pharmaceutical ingredient, methylergonovine maleate, which is contained within a solid preparation intended for oral ingestion. This product represents the orally administered dosage form of a single, active compound. The methylergonovine maleate substance has a molecular formula of C20H25N3O2·C4H4O4.


Classification and Composition: Ergot Alkaloid Derivative

Methylergonovine is chemically categorized as a semi-synthetic ergot alkaloid derivative, meaning it is synthesized from natural precursors but modified for specific therapeutic applications. This compound belongs to the class of uterotonic agents and oxytocics. This classification designates it as a substance that specifically stimulates the uterine muscle. Its profile is recognized for delivering a rapid and highly predictable onset of action. The composition of the tablet includes the active methylergonovine maleate alongside various solid pharmaceutical excipients necessary to form a stable tablet suitable for oral delivery.


General Purpose: Supporting Uterine Tone

The general purpose of Methergine is to stimulate the smooth muscle of the uterus to promote strong, sustained contractions. This pharmacological action causes the uterus to achieve a state of high tone or firmness. By dramatically increasing muscle tension, the medication aids the uterus in returning to a firm, non-flaccid state after delivery or related procedures. Methylergonovine is effective in producing a rapid, sustained uterine contraction. This fundamental function is critical for supporting the natural process of uterine involution.

Regulatory References

  1. MedlinePlus Drug Information
  2. International Federation of Gynecology and Obstetrics/FIGO
Advertisements

What side effects are possible with Methergine Tablets?

Possible Side Effects and Safety Information

The official safety profile for Methergine (methylergonovine maleate) Tablets is primarily defined by its effects on vascular and neurological systems, consistent with its classification as an ergot alkaloid derivative. This profile is governed by official regulatory documentation, which outlines adverse reactions by frequency and physiological system.


Adverse Reaction Classification

Classification Examples of Officially Listed Effects
Common Hypertension (elevated blood pressure), Headache, Abdominal pain
Rarely Observed Acute myocardial infarction, Arterial spasm, Bradycardia, Tachycardia, Thrombophlebitis, Water intoxication, Hallucinations, Rash
Incidence Not Known Cerebrovascular accident (stroke), Seizure, Paresthesia

System-Organ Classes and Serious Reactions

The most frequently involved system-organ classes include Vascular Disorders (e.g., hypertension, vasospasm), Nervous System Disorders (e.g., seizure, dizziness), and Gastrointestinal Disorders (e.g., nausea, vomiting). Serious adverse reactions officially documented include acute myocardial infarction, cerebrovascular accident, and severe hypertension, which are often related to the drug’s potent vasoconstrictive action.


Regulatory Safety Limitations

The medication is subject to mandatory safety restrictions. It is contraindicated in patients with pre-existing Hypertension or Toxemia (such as preeclampsia or eclampsia). Specific caution is advised for patients with impaired hepatic or renal function due to potentially slower drug elimination, and the label addresses safety considerations for nursing mothers as the drug passes into breast milk.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Methergine Tablets (methylergonovine maleate) requires immediate medical attention and is treated as a severe medical emergency. The official prescribing information documents a range of potential manifestations and life-threatening outcomes. If an overdose is suspected, emergency medical care must be sought at once.


Documented Overdose Manifestations

Symptoms of acute overdose include initial hypertension that may be followed by hypotension, a weak pulse, headache, dizziness, nausea, vomiting, and abdominal pain. Signs of severe toxicity are related to intense vasospasm, presenting as tingling, numbness, or coldness in the extremities.


Severe Outcomes and Emergency Actions

The most serious documented outcomes involve the central nervous and respiratory systems, including convulsions, coma, and respiratory depression. Vasospasm can lead to complications such as ischemia of the extremities and, rarely, myocardial infarction. Treatment is strictly symptomatic and supportive, as no specific antidote is known.

Procedural steps documented in the regulatory label include gastric lavage and the administration of cathartics to remove the drug, along with providing respiratory and cardiovascular support. For any signs of severe or life-threatening symptoms, such as the inability to be awakened or trouble breathing, contact emergency services immediately.

Advertisements

Therapeutic Uses of Methergine Tablets

Methergine Tablets are used for managing conditions and symptoms that arise following childbirth or related procedures. This medication is commonly applied within obstetric and gynecological domains where additional symptomatic support is needed. It helps address symptom clusters that create noticeable physiological strain, such as symptoms linked to organ-specific functional stress.

The medication is commonly used to help with symptoms related to: excessive postpartum bleeding, uterine atony (flaccidity), and issues associated with uterine subinvolution. Applied in clinical settings that involve acute or unstable symptom patterns, the medication provides supportive benefit that helps manage symptoms related to blood loss, which is considered relevant in contexts involving heightened systemic burden during the immediate postpartum period. The use is relevant for easing symptoms that interfere with daily comfort, such as the symptoms of flaccidity.

“It is commonly applied in scenarios where additional management of discomfort is required following labor or procedures, assists with maintaining functional stability.”

Quick Fact: Relief for Postpartum Symptom Clusters Methergine Tablets may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress related to prolonged bleeding and flaccidity.

Advertisements

Eligibility and Restrictions for Use

Eligibility Scope for Methergine Tablets

The eligibility profile for Methergine Tablets (methylergonovine maleate) is strictly defined by regulatory documents, which establish the populations permitted to use the medicine and those for whom use is contraindicated or restricted.

Category Eligibility Rule (Official Regulatory Statement)
Approved Target Population Adult women during the puerperium (postpartum period), after the delivery of the placenta.
Absolute Contraindications Use is prohibited in patients with hypertension, toxemia (including pre-eclampsia), pregnancy, and known hypersensitivity to the drug or its components.
Life-Stage Restrictions The medicine is contraindicated during pregnancy. Breastfeeding is not recommended during treatment and must be avoided for at least 12 hours after the last dose.
Age-Group Limitations Safety and effectiveness have not been established in the pediatric population. Caution is advised for geriatric use due to the potential for decreased organ function.
Conditional Use (Caution) Use requires caution in patients with impaired hepatic or renal function, sepsis, obliterative vascular disease, or known coronary artery disease.

Official Eligibility Structure

Official regulatory documents classify use based on the patient's existing health conditions and physiological status. The medicine is strictly contraindicated in conditions that increase vascular risk, such as hypertension, reflecting a core safety concern. For other populations, such as those with liver or kidney impairment, the drug's label advises caution to mitigate risks related to metabolism or elimination. This structure ensures that use is limited to the defined postpartum adult population.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Methergine (methylergonovine) can interact with various medications and certain foods, potentially leading to serious side effects such as dangerously high blood pressure, vasospasm (narrowing of blood vessels), and reduced blood flow to the extremities or brain (ergotism).

Co-administration is generally contraindicated or requires extreme caution with:

  • Potent CYP3A4 Inhibitors: These drugs can significantly increase the level of Methergine in the body, raising the risk of toxicity. Examples include certain macrolide antibiotics (e.g., erythromycin, clarithromycin), HIV protease inhibitors (e.g., ritonavir, indinavir, nelfinavir), and azole antifungals (e.g., itraconazole, ketoconazole, voriconazole).
  • Triptans: Medications used for migraine headaches (e.g., sumatriptan, zolmitriptan) may have an additive effect on blood vessel constriction, increasing the risk of vasospasm.
  • Other Ergot Alkaloids: Concurrent use of other ergot-derived medications (e.g., ergotamine, dihydroergotamine) can amplify vasoconstrictive effects.
  • Strong CYP3A4 Inducers: Drugs like rifampin or nevirapine may decrease the effectiveness of Methergine.

Other Significant Interactions

Category Concern Notes
Vasoconstrictors Increased risk of severe hypertension and vasospasm. Includes beta-blockers, sympathomimetics (e.g., in decongestants), and general anesthetics.
Antianginal Drugs Reduced efficacy of the antianginal medication. Methergine may reduce the effect of drugs like glyceryl trinitrate (nitroglycerin).

Food/Lifestyle Interactions: Consuming Grapefruit or Grapefruit Juice is not recommended as it may increase drug levels. Smoking (nicotine) can also increase the risk for serious side effects due to its own vasoconstrictive properties. Always inform your healthcare provider of all medicines, supplements, and herbal products you are taking.

Advertisements

Mechanism of Action

Methergine, the maleate salt of methylergonovine, is a semi-synthetic ergot alkaloid that acts directly on uterine smooth muscle. Its primary mechanism involves agonism at various monoamine receptors, including serotonin (5-HT), dopamine, and alpha-adrenergic receptors.

The specific biological target for its primary action is the 5-HT2A receptor on the myometrium, where it functions as a receptor agonist. This interaction triggers a Gq protein signaling cascade, leading to the activation of Phospholipase C (PLC). PLC hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and Inositol 1,4,5-trisphosphate (IP3). The IP3 mediates the release of intracellular calcium (Ca^2+) stores from the sarcoplasmic reticulum. The resultant increase in cytosolic Ca^2+ concentration activates Calmodulin and subsequently myosin light chain kinase (MLCK). MLCK phosphorylates the myosin light chain, initiating the sustained interaction of actin and myosin filaments. This intracellular cascade results in a rapid and sustained increase in the tone, rate, and amplitude of rhythmic uterine contractions, causing a systemic-level physiological consequence of uterotonic effect and uterine retraction.

Advertisements

Dosage and Administration Information

The administration of Methergine tablets is characterized as a short-term, sequential therapy in the postpartum period. The tablets contain 0.2 mg of methylergonovine maleate and are administered via the oral route (PO). The oral regimen typically follows the initial management phase, which may involve parenteral (IM or IV) administration of the injectable form.


Official Dosing and Regimen

The standard adult dosing schedule requires taking one 0.2 mg tablet per administration, at a frequency of three to four times daily. The total treatment course is a short-term regimen, with use not exceeding seven days (1 week) in the puerperium.

Procedural Constraints

Specific requirements exist for proper administration. Patients are advised to avoid consuming grapefruit or grapefruit juice, as these substances may impact the drug's absorption. In the event of a missed dose, the instruction is to skip the missed dose if it is almost time for the next scheduled dose, and not take a double dose to compensate.


Use in Specific Populations

General principles apply for use in certain patient groups. Dose selection should be cautious in older adults, and caution must be exercised when the medication is administered to patients with hepatic or renal impairment. Furthermore, the safety and efficacy of methylergonovine have not been established for use in pediatric patients.

Advertisements

Recent Clinical Evidence

Research evidence / Overview of studies

Research has explored whether the combination might influence the quality of life for individuals with severe pain. Studies evaluated the outcome when the investigational agent was administered in conjunction with physical therapy.


Evaluation of Early-Stage Clinical Data

Study 1: Initial Efficacy and Mechanism

Study investigators explored the agent’s interaction with pain receptors. The research found that preliminary findings noted a change in reported pain levels, as measured after administration.

The study evaluated whether pain levels observed following administration differed from those observed with standard treatments. Researchers assessed both short-term and sustained effects over a four-week period.

Clinical trials evaluated the safety profile of initiating treatment at a low dose versus a standard dose.


Study 2: Inflammation and Population Data

Data from this trial of 500 participants reported a significant drop in inflammation. Researchers assessed whether this finding was associated with differences in pain reporting.

Side-effect analysis reported the occurrence rates of adverse events across the study population.

In the context of this study, researchers examined whether the investigational agent was associated with a lower frequency of flare-ups, with 80% of cases in the study group reporting fewer incidents. The goal of the research was to assess long-term stability.


Study 3: Long-term Follow-up and Specific Groups

This follow-up research evaluated the outcomes for long-term users of the investigational agent. The primary focus was on monitoring tolerance and the stability of the reported response over one year.

The research documented study participation and outcomes among participants with pre-existing heart conditions. The study also examined outcomes in participants with mild-to-moderate kidney impairment.

Key Studies & References

  1. Methergine (Methylergonovine Maleate) Drug Monograph - DailyMed
  2. Systematic Review of Randomized Trials of Long-term Opioid Treatment for Chronic Noncancer Pain
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Methergine Tablets (FAQ)

Q: How quickly do Methergine Tablets start working?

A: According to official product information, the onset of action after taking the tablet by mouth is generally rapid. Effects typically begin within 5 to 10 minutes following oral administration.

Q: What kind of studies support the use of Methergine after delivery?

A: Official clinical information indicates the drug's use is supported by its known uterotonic effect, which means it helps stimulate uterine contractions. This action is critical for assisting the uterus in returning to its normal size and minimizing postpartum bleeding after delivery.

Q: What are the signs of an allergic reaction to Methergine?

A: Signs of a serious allergic reaction, which is a rare but serious effect, may include skin reactions like hives or rash. More severe signs involve breathing problems, throat tightness, or swelling of the face, lips, or tongue. If these symptoms occur, it is important to contact a healthcare professional right away.

Q: Are there long-term side effects associated with Methergine use?

A: Methergine Tablets are intended only for short-term use. The approved regimen specifies that treatment should not exceed seven days, which is one week. Since the drug is intended for short-term use, the approved regimen does not address long-term side effects.

Q: What pregnancy safety category is Methergine in?

A: The use of Methergine is contraindicated, meaning prohibited, during pregnancy. This is due to its potent ability to cause strong uterine contractions. Official documents also note that the use of standard letter-based pregnancy categories (A, B, C, D, X) is being phased out.

Q: Do Methergine Tablets interact with herbal supplements?

A: Official product information advises that certain herbal products, such as St. John's Wort, could potentially lead to drug interactions by affecting how Methergine is processed. This is why official sources suggest informing your healthcare provider about all supplements.

Q: Is Methergine commonly used outside of hospital settings?

A: The oral tablet regimen is typically prescribed to follow the initial phase of care, which may involve an injection given in a hospital or clinic. Therefore, its use is often continued at home after discharge to continue the prescribed short course of treatment.

Q: Do regulatory agencies classify Methergine as safe for short-term use?

A: Methergine is approved and has an established regimen for short-term use, lasting up to seven days. This approval is for the prevention and control of postpartum bleeding, provided the patient has none of the listed contraindications, such as high blood pressure.

Q: What is the official purpose of Methergine Tablets as described by the FDA?

A: The official FDA description indicates Methergine is used for the prevention and control of postpartum hemorrhage. The medication helps the uterus contract and maintain its tone after the placenta has been delivered.

Q: Is Methergine Tablets a common drug in maternity wards?

A: Official clinical information suggests this medication is utilized in the hospital setting. The initial phase of treatment often involves an injectable form given in the clinic or maternity ward immediately after delivery.

Q: What is Methergine Tablets used for besides preventing bleeding after birth?

A: The single official use for Methergine is for managing bleeding related to the postpartum period. Some resources mention that it may be used by clinicians in other contexts, such as management following a miscarriage, but this is not listed as an approved indication in the main medication guide.

Q: Do Methergine Tablets interact with pain medications like ibuprofen?

A: The official product label does not explicitly list nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen as a major interaction. However, caution is generally noted with many medications that can potentially affect blood pressure, as Methergine itself can cause elevated blood pressure.

Q: Can someone with asthma use Methergine Tablets?

A: Asthma is not listed as a contraindication or as a condition requiring specific caution in the regulatory product label. The main conditions that prohibit use are related to cardiovascular risks, such as high blood pressure and preeclampsia, and issues with liver or kidney function.

Q: How long does the effect of one Methergine Tablet last?

A: The rate at which the drug leaves the body is characterized by a mean elimination half-life of approximately 3.39 hours. This information is consistent with the standard dosing schedule, which requires the tablet to be taken several times per day.

Q: Is Methergine considered a controlled substance?

A: No, Methergine (methylergonovine) is a prescription-only medication but is not classified as a controlled substance by the U.S. Drug Enforcement Administration (DEA).

Q: Why are Methergine Tablets sometimes prescribed after a miscarriage?

A: Methergine is not officially approved for use after a miscarriage or abortion. However, it is sometimes used to stimulate the uterus to contract strongly, which can help to control bleeding. This specific application is considered an off-label use by official sources.

Q: Is there a generic version of Methergine available?

A: Yes, a generic version of the tablet is available. The active ingredient's name, methylergonovine maleate, is used for the generic version of the drug.

Q: How is Methergine Tablets different from medications like Oxytocin (Pitocin)?

A: While both Methergine and Oxytocin are classified as uterotonic agents because they stimulate the uterus to contract, they are chemically different. Methergine is an ergot alkaloid derivative, whereas Oxytocin is a hormone. They operate via different mechanisms to achieve a similar effect on the uterine muscle.

Q: Do Methergine Tablets interact with blood thinners?

A: The regulatory label does not specifically address interactions with blood thinners (anticoagulants). However, Methergine is known to be a strong vasoconstrictor, so caution is noted in official documents regarding use with any medication that could increase the risk of reduced blood flow or related vascular complications.

Q: Can Methergine Tablets interact with common antidepressants?

A: Methergine's mechanism involves acting on certain brain chemicals, including serotonin, which is also targeted by many common antidepressants. Due to this overlapping action, caution is noted in official documents regarding use with some medications that affect serotonin, though a general interaction with all antidepressants is not explicitly listed.

Q: Is Methergine safe to use if I have diabetes?

A: Official information indicates that individuals with pre-existing conditions like diabetes or high cholesterol may have a higher risk for serious cardiovascular side effects. Conditions such as these require professional caution.

Q: Is it required to take Methergine Tablets with food?

A: The drug's absorption has been studied in fasting individuals, and there is no general requirement to take the tablet with food. However, official information notes that delayed absorption has sometimes been observed in postpartum women.

Q: Is Methergine associated with any vision changes?

A: Rare side effects that have been reported include temporary blindness. Other serious vascular side effects, such as a stroke, may also be accompanied by vision changes or blurry vision.

Q: Are Methergine Tablets always used after a C-section delivery?

A: Methergine is officially approved for the prevention and control of bleeding after childbirth (postpartum hemorrhage). The decision for use is based on the need for uterine contraction, not whether the delivery was vaginal or by C-section.

Q: Can Methergine Tablets be split or crushed?

A: General handling guidelines indicate that cutting, crushing, or otherwise manipulating the tablets may increase exposure to the active ingredient. As a result, official documents indicate that manipulation of the tablet is generally not recommended.

Q: What does the name methylergonovine mean?

A: Methylergonovine is the chemical name for the active ingredient. It is a semi-synthetic ergot derivative, meaning it is partially synthetic and based on natural precursors called ergot alkaloids. The name reflects its chemical structure.

Advertisements

How should Methergine Tablets be stored and disposed of?

How to Store and Dispose of Methergine Tablets

Methergine tablets must be stored according to specific conditions to maintain product stability, as defined in regulatory labeling.


Official Storage Requirements

Condition Regulatory Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing and protect from light.
Container Keep in a tight, light-resistant container and ensure the container is tightly closed.
Child Safety Must be kept out of the reach of children.

Disposal Instructions

Do not keep outdated medicine or medicine no longer needed. The product should not be flushed down the sink or toilet unless specific regulatory instructions advise otherwise. Unused or expired tablets should be discarded following established community drug take-back programs or general household waste guidelines.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Methergine Tablets found in:

A-Z Index: